OBJECTIVE To determine whether antibiotic treatment for bacterial vaginosis or Trichomonas vaginalis during pregnancy decreases the risk of preterm birth and associated adverse outcomes. DATA SOURCES Pre-MEDLINE and MEDLINE (1966-2003), EMBASE (1980-2003), and the Cochrane Library were searched using the keywords "bacterial vaginosis", "Trichomonas", "Trichomonas vaginalis", "Trichomonas vagi...

background : trichomonas vaginalis is a pathogenic protozoon and may be contaminated with dsrna virus called trichomonas vaginalis virus (tvv). the viral infection is an important factor for its patho-genesis and sensitivity to metronidazole. the presence of tvv is associated with qualitative and quantitative expression of cysteine proteinases and surface immunogenic; p270. the purpose of this ...

1.Honigberg, G. and F. Mohn. 1973. An improved method for the isolation of highly polymerized native deoxyribonucleic acid from certain protozoa. J. Protozool. 20:146150. 2.Riley, D.E. and J.N. Krieger. 1992. Rapid and practical DNA isolation from Trichomonas vaginalis and other nuclease-rich protozoa. Mol. Biochem. Parasitol. 51:161164. 3.Rubino, S., R. Muresu, P. Rappelli,, P. Fiori, P. Rizzu...

background: metronidazole is drug of choice recommended by who for treatment of trichomoniasis, however, some reports claims drug resistance in trichomonas vaginalis isolates recently. the objective of this study was to determine the minimum lethal concentration (mlc) of metronidazole in resistant and sensitive strains, as well as genetic patterns of these stains by pcr method. methods : from f...

Six isolates of a strain (MRP-MT) of Trichomonas vaginalis obtained from a woman before and after unsuccessful treatment with metronidazole had an appreciably lower susceptibility to metronidazole both in vitro in the aerobic tube assay and in vivo in the mouse assay than did control strains from patients cured with standard doses of the drug. Our results support recent evidence that metronidaz...

The aim of this study is to estimate the prevalence of Trichomonas vaginalis and Candida albicans in low-risk patients treated at a first level clinic (primary health care represents the first level of contact of individuals, families, and the community with the system national health). Using a cross-sectional study in patients treated in clinical laboratory of the Sanitary District no. 7 of th...

The InPouch Trichomonas vaginalis test is the gold standard for clinical culture for Trichomonas vaginalis screening. The current package insert recommends an examination period of 3 days. After review of 2,499 InPouch tests spanning 13 years, we observed that examination up to 3 days will detect only 82.8% (95% confidence interval [CI], 79.0% to 86.2%) of positive specimens.

This study compared two assays for Trichomonas vaginalis detection, Gen-Probe's transcription-mediated amplification (TMA) assay for Trichomonas vaginalis and BTUB FRET PCR, using self-obtained clinical samples from 611 patients. Infection status was defined as two positive results by two different tests. The initial TMA assay sensitivity was 96.7%; specificity was 97.5%. The TMA assay was comp...

BACKGROUND Trichomonas vaginalis is a pathogenic protozoon and may be contaminated with dsRNA virus called Trichomonas vaginalis virus (TVV). The viral infection is an important factor for its pathogenesis and sensitivity to metronidazole. The presence of TVV is associated with qualitative and quantitative expression of cysteine proteinases and surface immunogenic; P270. The purpose of this stu...